Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • SCAI examines...

    SCAI examines strengths and weaknesses of sham PCI trial

    Written by Anjali Nimesh Nimesh Published On 2017-11-27T19:17:11+05:30  |  Updated On 27 Nov 2017 7:17 PM IST
    SCAI examines strengths and weaknesses of sham PCI trial

    This year, the Society for Cardiovascular Angiography and Interventions (SCAI) celebrated the forty-year anniversary of a groundbreaking procedure, now known as percutaneous coronary intervention (PCI), that has saved millions of lives and enhanced the lives of millions more. Four decades of clinical study have confirmed the benefit of PCI for patients with myocardial ischemia (insufficient blood flow to an area of the heart muscle). A new study presented today at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium in Denver questions the value of this revolutionary procedure in some patients.


    The Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) study was a small study that randomized 200 patients with stable ischemic heart disease to PCI or a sham procedure after a six-week period of intensive medical therapy optimization. The effectiveness of PCI was evaluated using exercise time on a treadmill six weeks after the procedure. The study found that exercise time for PCI-treated patients improved by 28.4 seconds, while sham-PCI treated patients increased exercise time by 11.8 seconds. This difference was not statistically significant. The trial did not assess longer-term effects of PCI, as participating patients and their physicians were unblinded after six weeks.


    SCAI, the world's leading society for interventional cardiologists, questions the conclusions of this study. SCAI has long stood by the conviction, based on abundant clinical evidence, that PCI is the preferred treatment for cardiac patients who need more than medicines to improve their health and quality of life.


    "We applaud the investigators for their innovative use of a sham procedure, but we're concerned about the reliability and interpretation of the findings. The number of patients studied was very small, so the study is far from conclusive. The primary endpoint used, exercise tolerance, is imprecise and very subjective: patient tolerance of exercise normally varies from week to week, so differences of a few seconds in exercise tolerance are hard to interpret," said SCAI President Kirk N. Garratt, MD, MSc, FSCAI. "Despite this, the improvement in exercise time among PCI patients was almost 2.5 times greater than in sham patients, suggesting PCI led to incremental improvement.


    "The most objective measure of ischemia relief in ORBITA was a secondary endpoint of heart performance called the DSE peak stress wall motion score index. This measure was significantly improved by PCI over sham treatment. Since PCI provides benefit by relieving ischemia, this test proved that PCI worked, and can provide added benefit even with optimal medical therapy," he continued.


    "Intensive medical treatment will reduce symptoms over the short run. In ORBITA, patients were given three times as many heart pills than they usually took during the six weeks before PCI or sham-PCI. Not surprisingly, patients improved: one out of every six patients had no symptoms after this. In 2017, we don't subject stable patients without symptoms to PCI, so this study doesn't properly reflect current PCI practice. Convenience and medication side effects are also big concerns for patients. This small study shouldn't overturn decades of study that have led to current practice standards," said Dr. Garratt.


    "ORBITA was undertaken because the investigators were concerned about the placebo effect. Of course, the placebo effect can be very powerful in the short term, but ischemia remained for these sham-treated patients. Since the hearts of sham-treated patients were still struggling with ischemia, I worry about the longer-term," Dr. Garratt stated. "Andreas Gruentzig, the inventor of angioplasty, advocated for rigorous study of the technique from the start. He would approve of using a sham procedure, but I think he would have demanded a larger, longer study with less subjective endpoints."


    Consistent research and innovation within the profession over the last four decades has proven that PCI relieves ischemia and improves function significantly in patients with stable heart disease. SCAI supports PCI and the interventional cardiologists who use it to save and enhance lives.

    Ischemiaischemic heart diseaseKirk N GarrattORBITAPCIpercutaneous coronary interventionSCAISociety for Cardiovascular Angiography and InterventionsTranscatheter Cardiovascular Therapeutics
    Source : Eureka Alert

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok